ProMIS Neurosciences announces publication on novel target for ALS

ProMIS Neurosciences announced a publication identifying Receptor for Activated C-Kinase 1 as a novel misfolded protein target for ALS and frontotemporal lobar degeneration. The article published in the online edition of Acta Neuropathologica Communications is titled, “Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.” “We are particularly pleased to have our data published in this well-regarded, peer-reviewed journal and contribute to the growing body of scientific knowledge on the pathogenic role of misfolded proteins in neurodegenerative diseases,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. “In addition, these data on RACK1 deliver another target for our pipeline as we advance clinical development of our lead product, PMN310, for Alzheimer’s disease.”